Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets

Despite the impressive impact of vaccines on public health, the success of vaccines targeting many important pathogens and cancers has to date been limited. The burden of infectious diseases today is mainly caused by antigenically variable pathogens (AVPs), which escape immune responses induced by p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Human vaccines & immunotherapeutics 2016-10, Vol.12 (10), p.2640-2648
Hauptverfasser: Servín-Blanco, R., Zamora-Alvarado, R., Gevorkian, G., Manoutcharian, K.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2648
container_issue 10
container_start_page 2640
container_title Human vaccines & immunotherapeutics
container_volume 12
creator Servín-Blanco, R.
Zamora-Alvarado, R.
Gevorkian, G.
Manoutcharian, K.
description Despite the impressive impact of vaccines on public health, the success of vaccines targeting many important pathogens and cancers has to date been limited. The burden of infectious diseases today is mainly caused by antigenically variable pathogens (AVPs), which escape immune responses induced by prior infection or vaccination through changes in molecular structures recognized by antibodies or T cells. Extensive genetic and antigenic variability is the major obstacle for the development of new or improved vaccines against "difficult" targets. Alternative, qualitatively new approaches leading to the generation of disease- and patient-specific vaccine immunogens that incorporate complex permanently changing epitope landscapes of intended targets accompanied by appropriate immunomodulators are urgently needed. In this review, we highlight some of the most critical common issues related to the development of vaccines against many pathogens and cancers that escape protective immune responses owing to antigenic variation, and discuss recent efforts to overcome the obstacles by applying alternative approaches for the rational design of new types of immunogens.
doi_str_mv 10.1080/21645515.2016.1191718
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_27295540</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826706665</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-b42e2a978d957f92be3f31dfc54d9a035920e10c4c4f058258232619698807e53</originalsourceid><addsrcrecordid>eNp9UU1rGzEQFaWlCWl-Qssee7EraVdaqYfSEPoFgVwayE2d1UrOFFlKJTnF_z4ydkxzqRjQ8ObNewOPkLeMLhlV9ANnchCCiSWnTC4Z02xk6gU53eELIYbbl8eeiRNyXspv2t5I-SDla3LCR64bjZ6SXxex4spFtN0DZIQJA9btx-56KhVscKVLsat3rssJ5q6mxrIWY8NhBRhL7WqGGSumCCFsuxm9R7sJDYe8crW8Ia88hOLOD_8Zufn65efl98XV9bcflxdXCztIVRfTwB0HPapZi9FrPrne92z2VgyzBtoLzalj1A528FQo3qrnkmmplaKjE_0Z-bTXvd9MazdbF9thwdxnXEPemgRonk8i3plVejCCKkGpagLvDwI5_dm4Us0ai3UhQHRpUwxTXI5USrnzEnuqzamU7PzRhlGzC8g8BWR2AZlDQG3v3b83Hree4miEz3sCRp_yGv6mHGZTYRtS9hmixWL6_3s8AgiAoOA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1826706665</pqid></control><display><type>article</type><title>Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Servín-Blanco, R. ; Zamora-Alvarado, R. ; Gevorkian, G. ; Manoutcharian, K.</creator><creatorcontrib>Servín-Blanco, R. ; Zamora-Alvarado, R. ; Gevorkian, G. ; Manoutcharian, K.</creatorcontrib><description>Despite the impressive impact of vaccines on public health, the success of vaccines targeting many important pathogens and cancers has to date been limited. The burden of infectious diseases today is mainly caused by antigenically variable pathogens (AVPs), which escape immune responses induced by prior infection or vaccination through changes in molecular structures recognized by antibodies or T cells. Extensive genetic and antigenic variability is the major obstacle for the development of new or improved vaccines against "difficult" targets. Alternative, qualitatively new approaches leading to the generation of disease- and patient-specific vaccine immunogens that incorporate complex permanently changing epitope landscapes of intended targets accompanied by appropriate immunomodulators are urgently needed. In this review, we highlight some of the most critical common issues related to the development of vaccines against many pathogens and cancers that escape protective immune responses owing to antigenic variation, and discuss recent efforts to overcome the obstacles by applying alternative approaches for the rational design of new types of immunogens.</description><identifier>ISSN: 2164-5515</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2016.1191718</identifier><identifier>PMID: 27295540</identifier><language>eng</language><publisher>United States: Taylor &amp; Francis</publisher><subject>Antigenic Variation ; antigenically variable pathogens ; cancer vaccine ; combinatorial peptide library ; Communicable Diseases - immunology ; Genetic Variation ; HIV vaccine ; Humans ; Neoplasms - immunology ; Review ; Vaccines - immunology ; Vaccines - isolation &amp; purification ; variable epitope library</subject><ispartof>Human vaccines &amp; immunotherapeutics, 2016-10, Vol.12 (10), p.2640-2648</ispartof><rights>2016 Taylor &amp; Francis 2016</rights><rights>2016 Taylor &amp; Francis 2016 Taylor &amp; Francis</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-b42e2a978d957f92be3f31dfc54d9a035920e10c4c4f058258232619698807e53</citedby><cites>FETCH-LOGICAL-c468t-b42e2a978d957f92be3f31dfc54d9a035920e10c4c4f058258232619698807e53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085008/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085008/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27295540$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Servín-Blanco, R.</creatorcontrib><creatorcontrib>Zamora-Alvarado, R.</creatorcontrib><creatorcontrib>Gevorkian, G.</creatorcontrib><creatorcontrib>Manoutcharian, K.</creatorcontrib><title>Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets</title><title>Human vaccines &amp; immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>Despite the impressive impact of vaccines on public health, the success of vaccines targeting many important pathogens and cancers has to date been limited. The burden of infectious diseases today is mainly caused by antigenically variable pathogens (AVPs), which escape immune responses induced by prior infection or vaccination through changes in molecular structures recognized by antibodies or T cells. Extensive genetic and antigenic variability is the major obstacle for the development of new or improved vaccines against "difficult" targets. Alternative, qualitatively new approaches leading to the generation of disease- and patient-specific vaccine immunogens that incorporate complex permanently changing epitope landscapes of intended targets accompanied by appropriate immunomodulators are urgently needed. In this review, we highlight some of the most critical common issues related to the development of vaccines against many pathogens and cancers that escape protective immune responses owing to antigenic variation, and discuss recent efforts to overcome the obstacles by applying alternative approaches for the rational design of new types of immunogens.</description><subject>Antigenic Variation</subject><subject>antigenically variable pathogens</subject><subject>cancer vaccine</subject><subject>combinatorial peptide library</subject><subject>Communicable Diseases - immunology</subject><subject>Genetic Variation</subject><subject>HIV vaccine</subject><subject>Humans</subject><subject>Neoplasms - immunology</subject><subject>Review</subject><subject>Vaccines - immunology</subject><subject>Vaccines - isolation &amp; purification</subject><subject>variable epitope library</subject><issn>2164-5515</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU1rGzEQFaWlCWl-Qssee7EraVdaqYfSEPoFgVwayE2d1UrOFFlKJTnF_z4ydkxzqRjQ8ObNewOPkLeMLhlV9ANnchCCiSWnTC4Z02xk6gU53eELIYbbl8eeiRNyXspv2t5I-SDla3LCR64bjZ6SXxex4spFtN0DZIQJA9btx-56KhVscKVLsat3rssJ5q6mxrIWY8NhBRhL7WqGGSumCCFsuxm9R7sJDYe8crW8Ia88hOLOD_8Zufn65efl98XV9bcflxdXCztIVRfTwB0HPapZi9FrPrne92z2VgyzBtoLzalj1A528FQo3qrnkmmplaKjE_0Z-bTXvd9MazdbF9thwdxnXEPemgRonk8i3plVejCCKkGpagLvDwI5_dm4Us0ai3UhQHRpUwxTXI5USrnzEnuqzamU7PzRhlGzC8g8BWR2AZlDQG3v3b83Hree4miEz3sCRp_yGv6mHGZTYRtS9hmixWL6_3s8AgiAoOA</recordid><startdate>20161002</startdate><enddate>20161002</enddate><creator>Servín-Blanco, R.</creator><creator>Zamora-Alvarado, R.</creator><creator>Gevorkian, G.</creator><creator>Manoutcharian, K.</creator><general>Taylor &amp; Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20161002</creationdate><title>Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets</title><author>Servín-Blanco, R. ; Zamora-Alvarado, R. ; Gevorkian, G. ; Manoutcharian, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-b42e2a978d957f92be3f31dfc54d9a035920e10c4c4f058258232619698807e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antigenic Variation</topic><topic>antigenically variable pathogens</topic><topic>cancer vaccine</topic><topic>combinatorial peptide library</topic><topic>Communicable Diseases - immunology</topic><topic>Genetic Variation</topic><topic>HIV vaccine</topic><topic>Humans</topic><topic>Neoplasms - immunology</topic><topic>Review</topic><topic>Vaccines - immunology</topic><topic>Vaccines - isolation &amp; purification</topic><topic>variable epitope library</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Servín-Blanco, R.</creatorcontrib><creatorcontrib>Zamora-Alvarado, R.</creatorcontrib><creatorcontrib>Gevorkian, G.</creatorcontrib><creatorcontrib>Manoutcharian, K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Human vaccines &amp; immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Servín-Blanco, R.</au><au>Zamora-Alvarado, R.</au><au>Gevorkian, G.</au><au>Manoutcharian, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets</atitle><jtitle>Human vaccines &amp; immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2016-10-02</date><risdate>2016</risdate><volume>12</volume><issue>10</issue><spage>2640</spage><epage>2648</epage><pages>2640-2648</pages><issn>2164-5515</issn><eissn>2164-554X</eissn><abstract>Despite the impressive impact of vaccines on public health, the success of vaccines targeting many important pathogens and cancers has to date been limited. The burden of infectious diseases today is mainly caused by antigenically variable pathogens (AVPs), which escape immune responses induced by prior infection or vaccination through changes in molecular structures recognized by antibodies or T cells. Extensive genetic and antigenic variability is the major obstacle for the development of new or improved vaccines against "difficult" targets. Alternative, qualitatively new approaches leading to the generation of disease- and patient-specific vaccine immunogens that incorporate complex permanently changing epitope landscapes of intended targets accompanied by appropriate immunomodulators are urgently needed. In this review, we highlight some of the most critical common issues related to the development of vaccines against many pathogens and cancers that escape protective immune responses owing to antigenic variation, and discuss recent efforts to overcome the obstacles by applying alternative approaches for the rational design of new types of immunogens.</abstract><cop>United States</cop><pub>Taylor &amp; Francis</pub><pmid>27295540</pmid><doi>10.1080/21645515.2016.1191718</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2164-5515
ispartof Human vaccines & immunotherapeutics, 2016-10, Vol.12 (10), p.2640-2648
issn 2164-5515
2164-554X
language eng
recordid cdi_pubmed_primary_27295540
source MEDLINE; PubMed Central; Alma/SFX Local Collection
subjects Antigenic Variation
antigenically variable pathogens
cancer vaccine
combinatorial peptide library
Communicable Diseases - immunology
Genetic Variation
HIV vaccine
Humans
Neoplasms - immunology
Review
Vaccines - immunology
Vaccines - isolation & purification
variable epitope library
title Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A41%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antigenic%20variability:%20Obstacles%20on%20the%20road%20to%20vaccines%20against%20traditionally%20difficult%20targets&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Serv%C3%ADn-Blanco,%20R.&rft.date=2016-10-02&rft.volume=12&rft.issue=10&rft.spage=2640&rft.epage=2648&rft.pages=2640-2648&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2016.1191718&rft_dat=%3Cproquest_pubme%3E1826706665%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1826706665&rft_id=info:pmid/27295540&rfr_iscdi=true